CMS reported successful phase 3 clinical trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis, with significantly higher patient improvement rates compared to placebo and minimal adverse events.

The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.

Merus reported positive interim data from its Phase II trial of petosemtamab in combination with pembrolizumab for first-line treatment of recurrent/metastatic HNSCC expressing PD-L1. The company also provided updates on its ongoing Phase III trials for petosemtamab and its collaboration programs.

The global generic oncology drugs market is expected to grow from $24.39 billion in 2025 to $30.99 billion by 2034, driven by rising cancer rates and demand for affordable treatments. The market is dominated by North America and is projected to see the fastest growth in Asia Pacific.

The atopic dermatitis drugs market is projected to reach $31 billion by 2034, driven by the rising prevalence of the condition, advancements in biologic therapies, and growing awareness. The biologics segment led the market in 2024, with new biologic injections targeting inflammatory pathways expanding treatment options.

Incyte's investigational drug povorcitinib met its primary endpoint in two phase 3 trials for treating moderate to severe hidradenitis suppurativa, but some analysts were expecting better results given the drug's performance in phase 2 trials. The drug will face competition from UCB's Bimzelx, which is already approved by the FDA.

Incyte reported mixed results from its late-stage Opzelura studies in prurigo nodularis, a skin condition with itchy firm lumps. The TRuE-PN1 study met its primary endpoint, but the TRuE-PN2 study missed statistical significance due to a high placebo response.

The immunotherapy in oncology market is projected to grow at a CAGR of 11.6%, reaching USD 319.5 billion by 2032. The patent landscape analysis report examines the dynamic interplay between innovation and industry growth, identifying emerging therapeutic targets and assessing the competitive landscape.

OPZELURA, a topical JAK inhibitor cream, has shown strong market growth driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Expanding reimbursement coverage and rising physician confidence contribute to its market penetration.

Incyte Corporation outlined a pivotal year ahead, with four potential drug launches in 2025 that could generate around $1 billion in incremental revenues by 2029. The company's pipeline includes promising candidates like povorcitinib, which targets multiple conditions with significant market opportunities.

CURE Media Group announced the recipients of the 2024 MPN Heroes Recognition Program, which honors individuals and organizations that have made significant contributions to the myeloproliferative neoplasm (MPN) community through advocacy, research, patient support, or healthcare innovation.

The article discusses the development of VEGFR-2 antagonists, a class of antineoplastic agents that block the binding of natural VEGF ligands to inhibit tumor angiogenesis. The pipeline includes 25+ active players and promising drug candidates in various stages of clinical trials.